Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats (Q41474268)

1 October 2017

Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats (English)

1 reference

1 October 2017

Lasse Bøllehuus Hansen

object named as

Lasse Bøllehuus Hansen

2

0 references

Peter Andersen

object named as

Peter Andersen

3

0 references

Else Marie Agger

4

object named as

Else Marie Agger

1 reference

1 October 2017

Lars Vibe Andreasen

1

1 reference

PubMed ID

25698487

1 October 2017

Jes Dietrich

5

1 reference

PubMed ID

25698487

1 October 2017

language of work or name

English

0 references

publication date

17 February 2015

1 reference

1 October 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

1 October 2017

33

1 reference

1 October 2017

1873-1879

1 reference

1 October 2017

15

1 reference

VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION *

1 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Implications of a circulating vaccine-derived poliovirus in Nigeria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Poliovirus vaccination options for achieving eradication and securing the endgame

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Polio vaccines: WHO position paper, January 2014--recommendations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Adjuvants and inactivated polio vaccine: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Aluminium compounds for use in vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Cooperation of B cells and T cells is required for survival of mice infected with vesicular stomatitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Cellular and humoral immune responses to poliovirus in mice: a role for helper T cells in heterotypic immunity to poliovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

How to predict the immune status of poliovirus vaccinees? A comparison of virus neutralization at a very low serum dilution versus ELISA in a cohort of infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

Distinct types of lung disease caused by functional subsets of antiviral T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

T-bet is required for protection against vaccinia virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.011

10.1016/J.VACCINE.2015.02.011

7 January 2021

Identifiers

DOI

1 reference

1 October 2017

1 reference

PubMed ID

25698487